Johnson & Johnson JNJ

$280.41 -0.37 (-0.13%)

Valuation

Market cap
679,126,272,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.94
P/E (forward)
24.85
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,383,003
Avg volume
7,225,794
Day's range
$276.59 – $281.16
Shares out
2,407,310,000
Stochastic %K
86%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

dewmoore Nov 11, 8:41 PM
$SLS Big Pharma drops billions on oncology, and the numbers speak for themselves: Gilead ($6B, 2020) paid $6B for Forty Seven& the AML drug FAILED its Phase 3 trials. (That $6B is our BASED... $SLS should be sitting around $30+ per share) Pfizer ($43B, 2023) bought Seagen for $43B ..it FAILED! (A $43B buyout valuation, $SLS hits $200 +per share) Merck (Keytruda) pulls in over $30 billion a year as the ultimate blockbuster oncology kingpin. (At $30B $SLS would sit around $140+ per share) Even better? Out of those 46 survivors, if GPS holds onto 21 of those survivors while the control arm takes the heavy bulk of the deaths, we WIN regardless! 21 GPS survivors easily BEATS the trial's required Hazard Ratio goal of 0.636 as the guy on X points out, the data suggests we won't just beat it—we will SHATTER it + end up with a SICK Hazard Ratio in the 0.1 to 0.3 range! 🚀. Popcorn is ready for earnings and topline data drop TODAY after 4pm !!! $PFE $MRK $JNJ $LLY GLTA!
1 replies
HydrogenH2 Nov 11, 7:44 PM
$JNJ Wake me up @ $250 when Fed increasing rates in December !!
0 replies
SellasgpsCurativeBAT11 Nov 11, 6:49 PM
$ABBV $BMY $JNJ $PFE $SLS We are approaching the final couple of hours which could potentially be the last quarterly report of Sellas as a stand alone Co. ✌️🙏❤️‍🩹
0 replies
UnMaker Nov 11, 6:23 PM
$BB Too many partnerships $AMD $GOOG $JNJ $AMZN
0 replies
BioTechHealthX Nov 11, 5:04 PM
$JNJ $LLY $TMO $UNH $DHR Changing expectations for Medicaid and ACA funding have investors reassessing healthcare stocks. These 5 companies offer distinct growth stories worth examining. https://biotechhealthx.com/biotech-news/5-healthcare-and-insurance-stocks-to-buy-as-democrats-take-control/
0 replies
Estimize Nov 11, 5:03 PM
Wall St is expecting 2.91 EPS for $JNJ Q4 [Reporting 01/26 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 replies
SellasgpsCurativeBAT11 Nov 11, 4:12 PM
$ABBV $BMY $JNJ $PFE $SLS I am looking forward to the Webcast/ press conference along with the Regal Pivotal Registrational Phase 3 study PRIMARY Top Line data. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Nov 11, 4:06 PM
$ABBV $BMY $JNJ $PFE $SLS I wouldn’t be surprised if data + deal come in the same PR! ✌️🙏❤️‍🩹
0 replies